TRP_1170x120_3-8-19

Novartis

Novartis and Sandoz honored with Power of Partnership Award

Novartis and Sandoz honored with Power of Partnership Award

STAMFORD, Conn. – Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Novartis and its Sandoz division, in recognition of their outstanding commitment to increasing access to health care around the world. Americares senior vice president of global programs Dr. E. Anne Peterson presented the award

Alcon acquires PowerVision Inc.

Alcon acquires PowerVision Inc.

FORT WORTH — Alcon, the global leader in eye care and a division of Novartis, announced Monday that it has acquired PowerVision, Inc., a privately-held, US-based medical device development company focused on creating fluid-based intraocular lens implants. The acquisition furthers Alcon’s commitment to bring this innovative, accommodating lens to cataract patients throughout the world. Commercial availability

Novartis announces change in Sandoz leadership

Novartis announces change in Sandoz leadership

BASEL –  Novartis announced this week that Richard Francis will be stepping down as chief executive officer of Sandoz, a Novartis division, and as a member of the executive committee of Novartis on March 31. Francesco Balestrieri, currently region head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.

Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life

Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life

BASEL — Novartis announced Tuesday additional results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx (secukinumab) compared to Stelara (ustekinumab) in delivering specific quality of life (QoL) aspects in adults with moderate-to-severe plaque psoriasis at 16 weeks. New CLARITY data show over two-thirds of Cosentyx treated patients with moderate to severe psoriasis reported no impact of

Sandoz enters into commercialization and supply agreement for insulin biosimilars

Sandoz enters into commercialization and supply agreement for insulin biosimilars

HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that it has entered into an agreement to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes. These medicines are currently in early and clinical stages of development for the European Union (E.U.),

Sandoz and Pear Therapeutics announce launch of reSET

Sandoz and Pear Therapeutics announce launch of reSET

HOLZKIRCHEN— Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch of reSET for patients with Substance Use Disorder (SUD). reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available. Study results from a multicenter, randomized clinical trial showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence

Sandoz receives U.S. FDA approval for biosimilar Hyrimoz

Sandoz receives U.S. FDA approval for biosimilar Hyrimoz

HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn’s

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

BASEL— Novartis today announced it has agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs. This transaction supports the Sandoz strategy of focusing on complex

Novartis seeks approval to spinoff Alcon eye care biz

Novartis seeks approval to spinoff Alcon eye care biz

BASEL — Novartis today announced its intention to spinoff Alcon, its eye care division, into a separately-traded standalone company. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. Completion of the transaction is subject to general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder

Novartis and Amgen announce FDA approval of Aimovig

Novartis and Amgen announce FDA approval of Aimovig

Basel, SWITZERLAND – Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to

Novartis announces FDA approval of Gilenya

Novartis announces FDA approval of Gilenya

EAST HANOVER, N.J. — Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for these patients. This approval expands the age range

New Novartis app enhances opthalmology trials

New Novartis app enhances opthalmology trials

BASEL, Switzerland — Novartis has launched the FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to

GSK to buy out Novartis in consumer health joint venture

GSK to buy out Novartis in consumer health joint venture

LONDON and BASEL, Switzerland — GlaxoSmithKline plc plans to buy Novartis’ 36.5% stake in their consumer health care joint venture for $13 billion. Under the agreement announced Tuesday, Novartis’ shares in the joint venture will be canceled, and the joint venture will pay the buyout price to Novartis. GSK has entered into a committed facilities agreement to

Sandoz releases Copaxone generic

Sandoz releases Copaxone generic

HOLZKIRCHEN, Germany — Following Food and Drug Administration final approval, Sandoz has launched of Glatopa 40 mg/ml (glatiramer acetate injection), a multiple sclerosis medication. The Novartis division said Tuesday that Glatopa 40 mg/ml, manufactured in the United States, was developed under a collaboration pact with Momenta Pharmaceuticals Inc. The product is a fully substitutable generic version of